CeNeS announces additional clinical data supporting the potential of M6G for the treatment of post-operative pain
CeNeS Pharmaceuticals notes the recent publication of additional clinical data on its lead product morphine-6-glucuronide (M6G) by an academic group at King’s College, London. The data, which was published in the international journal ‘Anesthesiology’ (1), provides further support for the potential of M6G as a treatment for post-operative pain, focusing on its potential for administration under patient-controlled analgesia (PCA). Part of this data has been presented previously at the 4th International Symposium for Nociceptive/Neuropathic Pain, King’s College Hospital.
The study, which was a randomised, double-blind study comparing the analgesic efficacy of M6G and morphine administered by initial bolus followed by PCA in 100 patients undergoing major joint replacement. Under the PCA system, patients administer their own pain relief as and when it is needed.
The key findings of the study are:
- M6G has analgesic potency similar to that of morphine. The authors speculate that the less effective pain control observed at early time points in this study in patients on M6G could be due to the need for a large loading dose or the product’s slower onset of action.
- There were clear differences between the M6G and morphine groups in terms of respiratory depression rates. The proportion of subjects with respiratory depression was markedly higher in the morphine group (27%) compared with the M6G group (6%).
- There was significantly less sedation in the M6G group in the immediate post-operative period as well as at the end of the 24 hour study period
- 24 hours post-surgery, when the nausea rate was at its highest, 41% of patients receiving morphine experienced nausea compared with 21% of those receiving M6G. However, this difference did not reach the level of statistical significance.
- The group concludes “it (M6G) has a unique pharmacodynamic profile with a better therapeutic window than morphine. Its simple, clean pharmacokinetic characteristics make it an attractive agent for further investigation…”
Commenting on the publication, Neil Clark, Chief Executive Officer of CeNeS said, “This new data adds further support to our reported clinical trial results and our belief in the potential of M6G as a new drug for the treatment of post-operative pain with significant advantages over morphine and other opiates. We believe that the less effective pain control observed with M6G at early time points in this study is due to the low loading doses used. Our first Phase III trial clearly showed that a higher loading dose of 30mg provides effective analgesia. This higher loading dose regime will be used in our second Phase III trial, which is expected to start in the next few months. If we are successful in demonstrating the efficacy and superior side effect profile of M6G compared to morphine in this large Phase III trial, which will involve approximately 440 patients, then we will have made a significant step towards the approval of the product in Europe.”
(1) Randomized, Double-blind Study of the Analgesic Efficacy of Morphine-6-Glucuronide versus Morphine Sulfate for Postoperative Pain in Major Surgery. Anesthesiology V 102, No 4, April 2005, pp 815-821
Rowan Minnion | alfa
The most recent press releases about innovation >>>
Die letzten 5 Focus-News des innovations-reports im Überblick:
In recent years, lasers with ultrashort pulses (USP) down to the femtosecond range have become established on an industrial scale. They could advance some applications with the much-lauded “cold ablation” – if that meant they would then achieve more throughput. A new generation of process engineering that will address this issue in particular will be discussed at the “4th UKP Workshop – Ultrafast Laser Technology” in April 2017.
Even back in the 1990s, scientists were comparing materials processing with nanosecond, picosecond and femtosesecond pulses. The result was surprising:...
Mapping the interaction of a single atom with a single photon may inform design of quantum devices
Have you ever wondered how you see the world? Vision is about photons of light, which are packets of energy, interacting with the atoms or molecules in what...
A multi-institutional research collaboration has created a novel approach for fabricating three-dimensional micro-optics through the shape-defined formation of porous silicon (PSi), with broad impacts in integrated optoelectronics, imaging, and photovoltaics.
Working with colleagues at Stanford and The Dow Chemical Company, researchers at the University of Illinois at Urbana-Champaign fabricated 3-D birefringent...
In experiments with magnetic atoms conducted at extremely low temperatures, scientists have demonstrated a unique phase of matter: The atoms form a new type of quantum liquid or quantum droplet state. These so called quantum droplets may preserve their form in absence of external confinement because of quantum effects. The joint team of experimental physicists from Innsbruck and theoretical physicists from Hannover report on their findings in the journal Physical Review X.
“Our Quantum droplets are in the gas phase but they still drop like a rock,” explains experimental physicist Francesca Ferlaino when talking about the...
The Max Planck Institute for Physics (MPP) is opening up a new research field. A workshop from November 21 - 22, 2016 will mark the start of activities for an innovative axion experiment. Axions are still only purely hypothetical particles. Their detection could solve two fundamental problems in particle physics: What dark matter consists of and why it has not yet been possible to directly observe a CP violation for the strong interaction.
The “MADMAX” project is the MPP’s commitment to axion research. Axions are so far only a theoretical prediction and are difficult to detect: on the one hand,...